Hennion & Walsh Asset Management Inc. Purchases 61,467 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 19.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,583 shares of the company’s stock after purchasing an additional 61,467 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $8,190,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of TEVA. Sanctuary Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after buying an additional 664 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after acquiring an additional 805 shares in the last quarter. DGS Capital Management LLC boosted its stake in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares during the last quarter. Smithfield Trust Co increased its holdings in Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Finally, Signaturefd LLC raised its stake in shares of Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.6 %

NYSE TEVA opened at $21.81 on Thursday. The stock has a market capitalization of $24.71 billion, a price-to-earnings ratio of -25.66, a PEG ratio of 1.06 and a beta of 0.73. The business’s fifty day moving average is $19.06 and its 200-day moving average is $18.14. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a one year low of $10.83 and a one year high of $22.80.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on TEVA shares. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.